MRK News 57.24 04/28/2014 05:48:20 Merck & Company (MRK)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck & Company (MRK) 57.24 $MRK

PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
M2 - 2 hrs 29 mins ago
Research and Markets (http://www.researchandmarkets.com/research/c8gl3q/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering. PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for prophylactic hepatitis B virus vaccines - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of prophylactic hepatitis B virus vaccines sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 3.1 Global Markets 3.1.1 Forecast 3.1.2 Drivers and Barriers - Global Issues 4 Current and Future Players 4.1 Overview 4.2 Trends in Corporate Strategy 4.3 Company Profiles 4.3.1 GSK 4.3.2 Merck 4.3.3 Sanofi 4.3.4 Kaketsuken 4.3.5 Dynavax Technologies 5 Appendix Companies Mentioned - GSK - Merck - Sanofi - Kaketsuken - Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/c8...harmapoint

Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - 2 hrs 44 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory

The 3 Dow Stocks to Watch This Week
Dan Caplinger, The Motley Fool - Motley Fool - Sun Apr 27, 6:05PM CDT
Earnings season isn't close to over, but we've already seen a huge number of stocks in the Dow Jones Industrials report their first-quarter results. So far, we've seen more companies do better than expected than do worse, but given the extent to...

The 3 Scariest Sectors in the Dow Jones Industrials
Dan Caplinger, The Motley Fool - Motley Fool - Sun Apr 27, 8:05AM CDT
Growth is an important part of the success of the stocks in the Dow Jones Industrials . Over the course of the five-year bull market, most of the Dow's components have shown that they can rebound from the depths of a deep recession. But lately,...

Hepatitis C Space Heats Up
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
What looked like a two-horse hepatitis C race between Gilead Sciences and AbbVie has gotten more interesting, with Merck and Bristol-Myers Squibb presenting data on their hepatitis C drugs at a scientific meeting earlier this month. ...

Why This Huge Dividend Stock Has Snoozed Through 2014
Dan Carroll, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
Pfizer 's one of big pharma's most recognizable names, and this Dow Jones member's recognized as one of the tried-and-true dividend giants among the market's blue-chip health-care stocks. Yet this company's had to fight back the patent cliff's...

Schedule for Upcoming Earnings Releases -- Research on Nokia, Boston Scientific, Merck & Co., and Bristol-Myers Squibb
PR Newswire - Fri Apr 25, 1:09PM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Nokia OYJ (NYSE: NOK), Boston Scientific Corp. (NYSE: BSX), Merck & Co. Inc. (NYSE: MRK) and Bristol-Myers Squibb Co. (NYSE: BMY). Full earnings notes on NOK, BSX, MRK and BMY can be downloaded upon signing up at:

Business events scheduled for the coming week
By The Associated Press - AP - Fri Apr 25, 12:58PM CDT
MONDAY, April 28

Andrzej S. Krolewski, MD, PhD, Receives American Diabetes Association's Kelly West Award for Outstanding Achievement in Epidemiology
Marketwire - Fri Apr 25, 11:00AM CDT
The American Diabetes Association will present the Kelly West Award for Outstanding Achievement in Epidemiology to Andrzej S. Krolewski, MD, PhD. Supported by an unrestricted educational grant from Merck, this award is given to an individual who has made significant contributions to the field of diabetes epidemiology. Dr. Krolewski will be recognized with this honor at the Association's 74th Scientific Sessions(R), taking place June 13-17, 2014, at the Moscone Center in San Francisco.

Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides

Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1613-100free.

Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Fri Apr 25, 5:30AM CDT
Merck KGaA (FRANKFURT: MRK)

Q1 Earnings: A Stronger Weakling than Originally Thought - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 25, 4:32AM CDT
Q1 Earnings: A Stronger Weakling than Originally Thought - Earnings Preview

Chugai Pharma USA Announces Appointment of Chief Medical Officer
PR Newswire - Fri Apr 25, 1:00AM CDT
Chugai Pharma USA, LLC (CPUSA), Berkeley Heights, NJ a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai) Tokyo, Japan, member of the Roche Group, appoints Athos Gianella-Borradori, M.D. as Chief Medical Officer of CPUSA.

What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Over the past five years, few drugs have been as highly anticipated as Gilead's Sovaldi, a new-generation oral treatment for hepatitis C infection. Sovaldi won FDA approval in December, and despite only being available for a few weeks, Sovaldi...

Fitch Affirms Merck & Co.'s Long-term IDR at 'A+'; Outlook Remains Negative
Business Wire - Thu Apr 24, 1:24PM CDT
Fitch Ratings has affirmed Merck & Co.'s (Merck) long-term ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating Outlook remains Negative. In addition, Fitch has affirmed the company's short-term ratings at 'F1'. A full list of rating actions follows at the end of this release.

Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global

Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1516-100free.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 81

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 195

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 8

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 13

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 25

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 15

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 138

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights on Paragon 28, Inc. Class Action Lawsuit

Updated Category News Views 106

Understanding the Paragon 28 Class Action Lawsuit Recently, investors in Paragon 28, Inc. have been alerted about a significant class action lawsuit involving the company's financial disclosures. The litigation revolves around potential inaccuracies in previously issued financial statements. Investors must be aware that the upcoming deadline to file a lead plaintiff...

Continue Reading
Newtopia Partners with Payvider for Enhanced Health Benefits

Updated Category News Views 278

Newtopia Partners with Payvider for Enhanced Health Benefits Newtopia Inc. (NEWU; NEWUF), a leader in tech-enabled habit change solutions, is thrilled to announce its new partnership with a supplemental insurance payvider. This exciting collaboration aims to provide Newtopia's successful habit change platform as a fully-covered benefit for thousands of workers in the...

Continue Reading
A4A Celebrates 250 Years of American Independence through Aviation

Updated Category News Views 94

A4A Launches Campaign for America's 250th Anniversary Airlines for America (A4A) is excited to unveil a memorable campaign, "Red, Flight & Blue—Celebrating America 250," which aims to celebrate the 250th anniversary of the United States. This significant campaign will utilize a variety of platforms, including social media, blog posts, and videos, to highlight the...

Continue Reading
Alexander’s Secures $400M Loan for New York Office Refinancing

Updated Category News Views 238

ALEXANDER’S, INC. concluded a hefty refinancing deal worth $400 million for its office condominium at 731 Lexington Avenue back in 2024. This isn’t just any property; it’s where Bloomberg LP hangs its hat—a landmark in the bustling New York City real estate scene. Traders were glued to this one because it wasn’t just about refinancing but about what it signals...

Continue Reading
IDV Secures Major Contract for Military Logistics Vehicles

Updated Category News Views 239

IDV Secures a Major Tender from the Dutch Armed Forces In a significant development for military logistics, IDV, part of the renowned Iveco Group (EXM: IVG), has successfully secured a contract with the Dutch Ministry of Defence. This contract entails supplying an impressive fleet of 785 military logistics vehicles, which includes three distinct versions: semitrailer...

Continue Reading